TKI dose reduction can effectively maintain major molecular remission in patients with chronic myeloid leukaemia

2020 ◽  
Author(s):  
Simone Claudiani ◽  
Jane F. Apperley ◽  
Richard Szydlo ◽  
Afzal Khan ◽  
George Nesr ◽  
...  
Keyword(s):  
Chronic Myeloid Leukaemia ◽  
Myeloid Leukaemia ◽  
Dose Reduction ◽  
Molecular Remission

Cell sorting enables interphase fluorescencein situhybridization detection of lowBCR-ABL1producing stem cells in chronic myeloid leukaemia patients beyond deep molecular remission

2013 ◽  
Vol 164 (1) ◽  
pp. 53-60 ◽  
Author(s):  
Peter B. van Kooten Niekerk ◽  
Charlotte C. Petersen ◽  
Charlotte G. Nyvold ◽  
Hans B. Ommen ◽  
Anne S. Roug ◽  
...  
Keyword(s):  
Stem Cells ◽  
Chronic Myeloid Leukaemia ◽  
Myeloid Leukaemia ◽  
Cell Sorting ◽  
Molecular Remission

scholarly journals Discontinuation of imatinib in children with chronic myeloid leukaemia in sustained deep molecular remission: results of the STOP IMAPED study

2019 ◽  
Vol 185 (4) ◽  
pp. 718-724 ◽  
Author(s):  
Clara M. A. de Bruijn ◽  
Frédéric Millot ◽  
Meinolf Suttorp ◽  
Marina Borisevich ◽  
Paul Brons ◽  
...  
Keyword(s):  
Chronic Myeloid Leukaemia ◽  
Myeloid Leukaemia ◽  
Molecular Remission

scholarly journals Food‐effect study of nilotinib in chronic myeloid leukaemia (NiFo study): Enabling dose reduction and relief of treatment burden

2020 ◽  
Vol 105 (2) ◽  
pp. 148-155
Author(s):  
Christel C. L. M. Boons ◽  
Yvonne M. Hartog ◽  
Jeroen J. W. M. Janssen ◽  
Anthe S. Zandvliet ◽  
René M. Vos ◽  
...  
Keyword(s):  
Chronic Myeloid Leukaemia ◽  
Myeloid Leukaemia ◽  
Dose Reduction ◽  
Food Effect ◽  
Effect Study ◽  
Treatment Burden

scholarly journals Prognostic significance of micro RNA 150 marker in BCR-ABL positive chronic myeloid leukaemia patients on imatinib mesylate

2017 ◽  
Vol 4 (5) ◽  
pp. 1557
Author(s):  
Obumneme B. Ezeanosike ◽  
Onyenmechi J. Afonne
Keyword(s):  
Chronic Myeloid Leukaemia ◽  
Myeloid Leukaemia ◽  
Imatinib Mesylate ◽  
Expression Patterns ◽  
Molecular Remission ◽  
Leukaemia Virus ◽  
Blood Samples ◽  
Total Rna ◽  
Spin Column ◽  
Micro Rnas

Background: Micro-RNAs control gene expression by destabilizing targeted transcripts and inhibiting their translation. In chronic myeloid leukaemia (CML), abnormal expressions of miRNAs have been described. The current treatment for newly diagnosed cases of CML is imatinib mesylate which produces rapid haematological responses. It is currently impossible to predict whether a patient will develop resistance to imatinib mesylate. This makes identification of predictors of resistance to imatinib an important goal in management of patients with CML. MicroRNA expression patterns can be used to predict outcome which can be remission or relapse. This study therefore, was set to assess the possible use of microRNA 150 for prognostication.Methods: Fifty peripheral blood samples previously collected from CML patients who were being treated with imatinib mesylate and stored in the refrigerator at +4°C were analyzed for the expression of microRNAs 150. Total RNA was extracted from guanidium isothiocynate (GITC) lysate of the blood samples using RNeasy mini spin column. The total RNA was converted to complimentary DNA by random hexamer priming using Murine Moloney Leukaemia Virus Reverse Transcriptase. Real time Multiplex PCR was used for detecting Breakpoint Cluster Region-Abelson Murine Leukaemia (BCR-ABL) transcript type.Results: The patients’ samples showed an expression of miRNA-150. Correlation of BCR-ABL ratio with miRNA-150 was done and the Spearman correlation coefficient (Rho) between BCR-ABL1 and miRNA-150 was 0.442 (p = 0.001; CI = 0.18-0.65) showing that there was a positive correlation between BCR-ABL1 and miRNA-150. The coefficient of determination was 20% (CI = 3-42%), which implies that about 20% of BCR-ABL1 ratio could be accounted for by the miRNA-150 values.Conclusions: Therefore, once patients who are on imatinib achieve molecular remission of the CML, the miRNA-150 can be useful in predicting outcome which could be relapse or complete molecular remission but is weak at diagnosis in predicting such outcome. 

Sign in / Sign up

Export Citation Format

Share Document